NCT03782467View on ClinicalTrials.gov

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

March 3, 2021

Study Completion Date

March 3, 2021

Conditions
Solid TumorNeoplasms
Interventions
BIOLOGICAL

ATOR-1015

Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)

Trial Locations (5)

DK-2100

Phase 1 Unit, Department of Oncology, Rigshospitalet, Copenhagen

DK-2730

Center for Cancer Research, Department of Oncology, Herlev Hospital, Herlev

SE-221 85

Kliniska Prövningsenheten, Kliniska Studier Sverige - Forum Söder, Skånes Universitetssjukhus, Lund

SE-171 64

Centrum för Kliniska Cancerstudier (CKC), Fas 1-enheten, Karolinska Universitetssjukhuset, Solna

SE-751 85

Onkologavdelningen, Akademiska Sjukhuset, Uppsala

Sponsors
All Listed Sponsors
lead

Alligator Bioscience AB

INDUSTRY

NCT03782467 - Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015 | Biotech Hunter | Biotech Hunter